Related Experiment Videos
CA 15.3 in nonmalignant liver diseases.
J Collazos1, J Genollá, A Ruibal
1Internal Medicine Service, Hospital de Galdacano, Vizcaya, Spain.
The International Journal of Biological Markers
|July 1, 1991
Summary
Cancer antigen 15.3 (CA 15.3) can be monitored in patients with benign liver diseases. Abnormal CA 15.3 levels were observed in some patients, correlating with liver dysfunction and IgA levels.
Area of Science:
- Clinical Biochemistry
- Oncology
- Hepatology
Background:
- Cancer antigen 15.3 (CA 15.3) is a tumor marker primarily used for monitoring breast carcinoma.
- Its behavior in patients with benign liver diseases requires further investigation.
Purpose of the Study:
- To evaluate the behavior and clinical significance of CA 15.3 in patients with benign diffuse hepatic diseases.
- To determine the correlation between CA 15.3 levels and specific biochemical parameters in liver disease.
Main Methods:
- Serum CA 15.3 levels were assessed in 161 patients with benign diffuse hepatic diseases.
- Patients underwent comprehensive clinical and biochemical evaluations.
- Correlations between CA 15.3 and liver disease parameters, including IgA, were analyzed.
Main Results:
- Abnormal serum CA 15.3 levels were detected in 8.7% of patients (11.6% of cirrhotics, 5.3% of noncirrhotics).
- Immunoglobulin A (IgA) showed the strongest correlation with CA 15.3 (r = 0.39, p < 0.00001).
- Hepatocellular dysfunction was associated with increased CA 15.3 levels, despite a low false-positive rate.
Conclusions:
- CA 15.3 exhibits altered levels in patients with benign liver diseases, particularly those with hepatocellular dysfunction.
- Normal IgA levels are a strong indicator of normal CA 15.3 levels.
- CA 15.3 can potentially be utilized as a tumor marker in these patients within standard reference ranges.